clinical trial · NCT05260073
Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis
Almirall, S.A.·—·completed·n = 300
Keratosis, ActinicTirbanibulin
brief summary
The purpose of the study is to evaluate patient reported outcomes (PROs) in terms of health-related quality of life (HRQoL) among subjects with actinic keratosis (AK).
started
Mar 9, 2022
primary completion
Oct 31, 2022
completion
Mar 7, 2023
last updated
Sep 20, 2024
official title
A Prospective Cohort Study of Patients With Actinic Keratosis (AK) in the Face or Scalp Treated With Tirbanibulin and Followed for 24 Weeks Post Treatment-initiation. Patient Reported Outcomes (PROs) and Clinical Profile of Patients Will be Gathered for Descriptive Analyses of Patient Outcomes Over the 24-week Study Observation Period
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol